Serum IGF-1 is insufficient to restore skeletal size in the total absence of the growth hormone receptor
Source: Wu Y et al J Bone Miner Res. 2013 Mar 3. doi: 10.1002/jbmr.1920. Organisation: David B. Kriser Dental Center, Department of Basic Science and Craniofacial Biology, New York University College of Dentistry, New York, NY 10010; College of Integrative Medicine and Institute of Integrative Medicine, Dalian Medical University, Dalian, China.
States of growth hormone (GH) resistance, such those observed in Laron's dwarf patients, are characterized by mutations in the GH receptor (GHR), decreased serum and tissue IGF-1 levels, impaired glucose tolerance, and impaired skeletal acquisition. IGF-1 replacement therapy in such patients increases growth velocity but does not normalize growth. Herein we combined the GH-resistant (GHR knockout, GHRKO) mouse model with mice expressing the hepatic Igf-1 transgene (HIT) to generate the GHRKO-HIT mouse model. In GHRKO-HIT mice, serum IGF-1 levels were restored via transgenic expression of Igf-1, allowing us to study how endocrine IGF-1 affects growth, metabolic homeostasis, and skeletal integrity. We show that in a GH-resistant state, normalization of serum IGF-1 improved body adiposity and restored glucose tolerance but was insufficient to support normal skeletal growth, resulting in an osteopenic skeletal phenotype. The inability of serum IGF-1 to restore skeletal integrity in the total absence of GHR likely resulted from reduced skeletal Igf-1 gene expression, blunted GH-mediated effects on the skeleton that are independent of serum or tissue IGF-1, and from poor delivery of IGF-1 to the tissues. These findings are consistent with clinical data showing that IGF-I replacement therapy in patients with Laron's syndrome does not achieve full skeletal growth. (c) 2013 American Society for Bone and Mineral Research
SciBite is an information technology company serving the biotech and bio-pharma sector. We provide
competitive intelligence services with a difference, serving
this pharma news in real time, tagging mentions of targets,
indications, companies, drugs and technologies of interest to those involved in human
health and drug discovery. We provide a free newsletter service to allow everyone to
explore the therapeutic landscape, stay informed and data mine for new drug repurposing and portfolio
All of this is done via our novel text-mining technology that can be used for a wide variety of
applications within life-sciences.
Usage subject to acceptance of our Terms Of Service. For SCIENTIFIC RESEARCH PURPOSES ONLY. Not be used for any other purpose
Built With Grateful Acknowledgement Of Contributing Sources